Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients
Conclusions This study indicates that LBM and drug monitoring may be helpful in the management of sunitinib-treated patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Investigational New Drugs | Kidney Cancer | Study | Thrombocytopenia | Toxicology